Actions of l-thyroxine and Nano-diamino-tetrac (Nanotetrac) on PD-L1 in cancer cells

Hung Yun Lin, Yu-Tang Chin, André Wendindondé Nana, Ya-Jung Shih, Hsuan-Yu Lai, Heng-Yuan Tang, Matthew Leinung, Shaker A. Mousa, Paul J. Davis

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The PD-1 (programmed death-1)/PD-L1 (PD-ligand 1) checkpoint is a critical regulator of activated T cell-cancer cell interactions, defending tumor cells against immune destruction. Nano-diamino-tetrac (NDAT; Nanotetrac) is an anticancer/anti-angiogenic agent targeted to the thyroid hormone-tetrac receptor on the extracellular domain of integrin αvβ3. NDAT inhibits the cancer cell PI3-K and MAPK signal transduction pathways that are critical to PD-L1 gene expression. We examined actions in vitro of thyroid hormone (l-thyroxine, T4) and NDAT on PD-L1 mRNA abundance (qPCR) and PD-L1 protein content in human breast cancer (MDA-MB-231) cells and colon carcinoma (HCT116 and HT-29) cells. In MDA-MB-231 cells, a physiological concentration of T4 (10-7 M total; 10-10 M free hormone) stimulated PD-L1 gene expression by 38% and increased PD-L1 protein by 2.7-fold (p -7 M) reduced PD-L1 in T4-exposed cells by 21% (mRNA) and 39% (protein) (p 4 enhanced PD-L1 gene expression by 17% and protein content by 24% (p 4-treated cells lowered mRNA by 33% and protein by 66%. In HT-29 cells, T4 increased PD-L1 mRNA by 62% and protein by 27%. NDAT lowered basal and T4-stimulated responses in PD-L1 mRNA and protein by 35-40% (p 4-induced PD-L1 accumulation. We propose that, by a nongenomic mechanism, endogenous T4 may clinically support activity of the defensive PD-1/PD-L1 checkpoint in tumor cells. NDAT non-immunologically suppresses basal and T4-induced PD-L1 gene expression and protein accumulation in cancer cells.

Original languageEnglish
JournalSteroids
DOIs
Publication statusAccepted/In press - Jan 28 2016

Fingerprint

Thyroxine
Cells
Gene expression
Neoplasms
Proteins
Messenger RNA
Gene Expression
HT29 Cells
Tumors
CD4-Positive T-Lymphocytes
Thyroid Hormone Receptors
Signal transduction
T-cells
tetraiodothyroacetic acid
Thyroid Hormones
Integrins
Cell Communication
Signal Transduction
Colon
Hormones

Keywords

  • Breast carcinoma
  • Cancer immunotherapy
  • Colon carcinoma
  • l-Thyroxine (T)
  • Programmed death ligand 1

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Molecular Biology
  • Organic Chemistry
  • Pharmacology

Cite this

Lin, H. Y., Chin, Y-T., Nana, A. W., Shih, Y-J., Lai, H-Y., Tang, H-Y., ... Davis, P. J. (Accepted/In press). Actions of l-thyroxine and Nano-diamino-tetrac (Nanotetrac) on PD-L1 in cancer cells. Steroids. https://doi.org/10.1016/j.steroids.2016.05.006

Actions of l-thyroxine and Nano-diamino-tetrac (Nanotetrac) on PD-L1 in cancer cells. / Lin, Hung Yun; Chin, Yu-Tang; Nana, André Wendindondé; Shih, Ya-Jung; Lai, Hsuan-Yu; Tang, Heng-Yuan; Leinung, Matthew; Mousa, Shaker A.; Davis, Paul J.

In: Steroids, 28.01.2016.

Research output: Contribution to journalArticle

Lin, HY, Chin, Y-T, Nana, AW, Shih, Y-J, Lai, H-Y, Tang, H-Y, Leinung, M, Mousa, SA & Davis, PJ 2016, 'Actions of l-thyroxine and Nano-diamino-tetrac (Nanotetrac) on PD-L1 in cancer cells', Steroids. https://doi.org/10.1016/j.steroids.2016.05.006
Lin, Hung Yun ; Chin, Yu-Tang ; Nana, André Wendindondé ; Shih, Ya-Jung ; Lai, Hsuan-Yu ; Tang, Heng-Yuan ; Leinung, Matthew ; Mousa, Shaker A. ; Davis, Paul J. / Actions of l-thyroxine and Nano-diamino-tetrac (Nanotetrac) on PD-L1 in cancer cells. In: Steroids. 2016.
@article{0d3fe4d522054111bc09508cfc5d4c71,
title = "Actions of l-thyroxine and Nano-diamino-tetrac (Nanotetrac) on PD-L1 in cancer cells",
abstract = "The PD-1 (programmed death-1)/PD-L1 (PD-ligand 1) checkpoint is a critical regulator of activated T cell-cancer cell interactions, defending tumor cells against immune destruction. Nano-diamino-tetrac (NDAT; Nanotetrac) is an anticancer/anti-angiogenic agent targeted to the thyroid hormone-tetrac receptor on the extracellular domain of integrin αvβ3. NDAT inhibits the cancer cell PI3-K and MAPK signal transduction pathways that are critical to PD-L1 gene expression. We examined actions in vitro of thyroid hormone (l-thyroxine, T4) and NDAT on PD-L1 mRNA abundance (qPCR) and PD-L1 protein content in human breast cancer (MDA-MB-231) cells and colon carcinoma (HCT116 and HT-29) cells. In MDA-MB-231 cells, a physiological concentration of T4 (10-7 M total; 10-10 M free hormone) stimulated PD-L1 gene expression by 38{\%} and increased PD-L1 protein by 2.7-fold (p -7 M) reduced PD-L1 in T4-exposed cells by 21{\%} (mRNA) and 39{\%} (protein) (p 4 enhanced PD-L1 gene expression by 17{\%} and protein content by 24{\%} (p 4-treated cells lowered mRNA by 33{\%} and protein by 66{\%}. In HT-29 cells, T4 increased PD-L1 mRNA by 62{\%} and protein by 27{\%}. NDAT lowered basal and T4-stimulated responses in PD-L1 mRNA and protein by 35-40{\%} (p 4-induced PD-L1 accumulation. We propose that, by a nongenomic mechanism, endogenous T4 may clinically support activity of the defensive PD-1/PD-L1 checkpoint in tumor cells. NDAT non-immunologically suppresses basal and T4-induced PD-L1 gene expression and protein accumulation in cancer cells.",
keywords = "Breast carcinoma, Cancer immunotherapy, Colon carcinoma, l-Thyroxine (T), Programmed death ligand 1",
author = "Lin, {Hung Yun} and Yu-Tang Chin and Nana, {Andr{\'e} Wendindond{\'e}} and Ya-Jung Shih and Hsuan-Yu Lai and Heng-Yuan Tang and Matthew Leinung and Mousa, {Shaker A.} and Davis, {Paul J.}",
year = "2016",
month = "1",
day = "28",
doi = "10.1016/j.steroids.2016.05.006",
language = "English",
journal = "Steroids",
issn = "0039-128X",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Actions of l-thyroxine and Nano-diamino-tetrac (Nanotetrac) on PD-L1 in cancer cells

AU - Lin, Hung Yun

AU - Chin, Yu-Tang

AU - Nana, André Wendindondé

AU - Shih, Ya-Jung

AU - Lai, Hsuan-Yu

AU - Tang, Heng-Yuan

AU - Leinung, Matthew

AU - Mousa, Shaker A.

AU - Davis, Paul J.

PY - 2016/1/28

Y1 - 2016/1/28

N2 - The PD-1 (programmed death-1)/PD-L1 (PD-ligand 1) checkpoint is a critical regulator of activated T cell-cancer cell interactions, defending tumor cells against immune destruction. Nano-diamino-tetrac (NDAT; Nanotetrac) is an anticancer/anti-angiogenic agent targeted to the thyroid hormone-tetrac receptor on the extracellular domain of integrin αvβ3. NDAT inhibits the cancer cell PI3-K and MAPK signal transduction pathways that are critical to PD-L1 gene expression. We examined actions in vitro of thyroid hormone (l-thyroxine, T4) and NDAT on PD-L1 mRNA abundance (qPCR) and PD-L1 protein content in human breast cancer (MDA-MB-231) cells and colon carcinoma (HCT116 and HT-29) cells. In MDA-MB-231 cells, a physiological concentration of T4 (10-7 M total; 10-10 M free hormone) stimulated PD-L1 gene expression by 38% and increased PD-L1 protein by 2.7-fold (p -7 M) reduced PD-L1 in T4-exposed cells by 21% (mRNA) and 39% (protein) (p 4 enhanced PD-L1 gene expression by 17% and protein content by 24% (p 4-treated cells lowered mRNA by 33% and protein by 66%. In HT-29 cells, T4 increased PD-L1 mRNA by 62% and protein by 27%. NDAT lowered basal and T4-stimulated responses in PD-L1 mRNA and protein by 35-40% (p 4-induced PD-L1 accumulation. We propose that, by a nongenomic mechanism, endogenous T4 may clinically support activity of the defensive PD-1/PD-L1 checkpoint in tumor cells. NDAT non-immunologically suppresses basal and T4-induced PD-L1 gene expression and protein accumulation in cancer cells.

AB - The PD-1 (programmed death-1)/PD-L1 (PD-ligand 1) checkpoint is a critical regulator of activated T cell-cancer cell interactions, defending tumor cells against immune destruction. Nano-diamino-tetrac (NDAT; Nanotetrac) is an anticancer/anti-angiogenic agent targeted to the thyroid hormone-tetrac receptor on the extracellular domain of integrin αvβ3. NDAT inhibits the cancer cell PI3-K and MAPK signal transduction pathways that are critical to PD-L1 gene expression. We examined actions in vitro of thyroid hormone (l-thyroxine, T4) and NDAT on PD-L1 mRNA abundance (qPCR) and PD-L1 protein content in human breast cancer (MDA-MB-231) cells and colon carcinoma (HCT116 and HT-29) cells. In MDA-MB-231 cells, a physiological concentration of T4 (10-7 M total; 10-10 M free hormone) stimulated PD-L1 gene expression by 38% and increased PD-L1 protein by 2.7-fold (p -7 M) reduced PD-L1 in T4-exposed cells by 21% (mRNA) and 39% (protein) (p 4 enhanced PD-L1 gene expression by 17% and protein content by 24% (p 4-treated cells lowered mRNA by 33% and protein by 66%. In HT-29 cells, T4 increased PD-L1 mRNA by 62% and protein by 27%. NDAT lowered basal and T4-stimulated responses in PD-L1 mRNA and protein by 35-40% (p 4-induced PD-L1 accumulation. We propose that, by a nongenomic mechanism, endogenous T4 may clinically support activity of the defensive PD-1/PD-L1 checkpoint in tumor cells. NDAT non-immunologically suppresses basal and T4-induced PD-L1 gene expression and protein accumulation in cancer cells.

KW - Breast carcinoma

KW - Cancer immunotherapy

KW - Colon carcinoma

KW - l-Thyroxine (T)

KW - Programmed death ligand 1

UR - http://www.scopus.com/inward/record.url?scp=84975132417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975132417&partnerID=8YFLogxK

U2 - 10.1016/j.steroids.2016.05.006

DO - 10.1016/j.steroids.2016.05.006

M3 - Article

JO - Steroids

JF - Steroids

SN - 0039-128X

ER -